Structure—Activity Relationships of the Oxindole Growth Hormone Secretagogues.

Tokunaga, Teruhisa; Hume, W. Ewan; Nagamine, Jun; Kawamura, Tetsuya; Taiji, Mutsuo; Nagata, Ryu

doi:10.1002/chin.200530102

Cited by 6 publications

(8 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The nonpeptide compounds 191) (Patchett et al, 1995) and L-692,429 (MK-751) (Smith et al, 1993) were kindly provided by Andrew Howard (Merck Research Laboratories, Rahway, NJ). SM-130686 and SM-157740 (Tokunaga et al, 2005) were kindly provided by Ryu Nagata (Dainippon Sumitomo Pharma Co., Osaka, Japan).…”

Section: Methodsmentioning

confidence: 99%

“…However, subsequent series based on the spiropiperidine privileged structure, MK-677 being the most advanced prototype compound, exhibited favorable in vivo properties and have been investigated in several human clinical studies, including a phase II study for bone healing. A number of different series of nonpeptide GHS compounds, inspired by this pioneering work, were subsequently developed at different companies, including the highly conformationally constrained oxindole compounds from Tokunaga et al (2001Tokunaga et al ( , 2005 (Fig. 1).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Overlapping Binding Site for the Endogenous Agonist, Small-Molecule Agonists, and Ago-allosteric Modulators on the Ghrelin Receptor

Holst

Frimurer²,

Mokrosiński³

et al. 2008

Mol Pharmacol

View full text Add to dashboard Cite

A library of robust ghrelin receptor mutants with single substitutions at 22 positions in the main ligand-binding pocket was employed to map binding sites for six different agonists: two peptides (the 28-amino-acid octanoylated endogenous ligand ghrelin and the hexapeptide growth hormone secretagogue GHRP-6) plus four nonpeptide agonists-the original benzolactam L-692,429 [3-amino-3-methyl-N-(2,3,4,5-The strongest mutational effect with respect to decrease in potency for stimulation of inositol phosphate turnover was for all six agonists the GluIII:09-to-Gln substitution in the extracellular segment of TM-III. Likewise, all six agonists were affected by substitutions of PheVI:16, ArgVI:20, and PheVI:23 on the opposing face of transmembrane domain (TM) VI. Each of the agonists was also affected selectively by specific mutations. The mutational map of the ability of L-692,429 and GHRP-6 to act as allosteric modulators by increasing ghrelin's maximal efficacy overlapped with the common mutational map for agonism but it was not identical with the map for the agonist property of these small-molecule ligands. In molecular models, built over the inactive conformation of rhodopsin, low energy conformations of the nonpeptide agonists could be docked to satisfy many of their mutational hits. It is concluded that although each of the ligands in addition exploits other parts of the receptor, a large, common binding site for both small-molecule agonists-including ago-allosteric modulators-and the endogenous agonist is found on the opposing faces of TM-III and -VI of the ghrelin receptor.The gastrointestinal peptide hormone ghrelin is an important regulator of appetite, energy expenditure, and acute growth hormone secretion through interaction with the ghrelin receptors located mainly in the central nervous system (Tschöp et al., 2000). From a drug discovery point of view, these functions of ghrelin qualify ghrelin receptor agonists as anabolic compounds with potentials for treatment of, for example, cachexia.The initial agonists synthesized for the ghrelin receptor were peptides, sharing common structural features, including a central hydrophobic motif and a positive charge in the amidated C-terminal end. Despite relatively poor bioavailability and low therapeutic index/window, these peptides efficiently induced GH secretion in vitro as well as in vivo both in animal and human models (Bowers et al., 1984). GHRP-6 is a prototype for these peptides (Fig. 1). In an attempt to increase oral bioavailability, a series of nonpeptide compounds was subsequently developed. They were

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

Overlapping Binding Site for the Endogenous Agonist, Small-Molecule Agonists, and Ago-allosteric Modulators on the Ghrelin Receptor

Holst

Frimurer²,

Mokrosiński³

et al. 2008

Mol Pharmacol

View full text Add to dashboard Cite

show abstract

“…Administered orally, compound 19c increases body weight at the doses of 2-20 mg/kg twice a day for 4 days 108]. It exerts a greater effect than that exerted by compound 19b [107] at the corresponding doses, and it has an oral bioavailability in rats of 28% [108]. …”

Section: Oxindolesmentioning

confidence: 99%

“…§ Displacement of [ 125 I]-ghrelin to hGHSR expressed in CHO cells[108]. ¶ Growth hormone-releasing assay in rat cultured pituitary cells[108].…”

mentioning

confidence: 99%

Ghrelin Receptor Modulators and Their Therapeutic Potential

Costantino

Barlocco

2009

Future Med. Chem.

View full text Add to dashboard Cite

show abstract

“…Indolin-2-one is a most advantageous scaffold which represents an important class of heterocyclic compounds endowed with interesting pharmacological activities such as antimicrobial [3], antioxidant [4], antiviral [5], anti-cholinesterase [6], antibacterial [7], histone deacetylase [8], and anticancer activities [9,10]. Besides, SU4984, SU6668 and BIBF1120 (Figure 1) are the binding with bio-macromolecules like Deoxyribonucleic acid (DNA) has received immense attention since this association can regulate many biochemical functions that take place in cellular system [19].…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Anti-Proliferative Activity of Biphenyl Derived 5-Substituted-Indolin-2-Ones

Meti¹,

Kamble²,

Kamble³

et al. 2017

Arch Chem Res

View full text Add to dashboard Cite

A series of novel biphenyl derived 5-substituted-indolin-2-one derivatives were synthesized by the reaction of 6-chloro-5-(2-chloroethyl)-indolin-2-one 1 with cyclic secondary amines 2a-h followed by condensation of bromomethylcyanobiphenyl to afford the compounds 5a-h. The nitrile group of 5a-h was converted into tetrazole to obtain the compounds 7a-h and tetrazole of 7a-h was further ring transformed into oxadiazole to get compounds 8a-h. Molecular docking study of these previously unknown molecules was performed on PDB: 453D to analyze the interaction and preferred binding mode of synthesized molecules with DNA. Anti-proliferative activity of these newly synthesized compounds were evaluated against a panel of 60 human cancer cell lines at National Cancer Institute (NCI), Bethesda USA. Among these, seven (07) compounds were evaluated for their anticancer activity. Some of the compounds displayed potent anti-proliferative activity at 10 µM.

show abstract

Structure—Activity Relationships of the Oxindole Growth Hormone Secretagogues.

Cited by 6 publications

References 1 publication

Overlapping Binding Site for the Endogenous Agonist, Small-Molecule Agonists, and Ago-allosteric Modulators on the Ghrelin Receptor

Overlapping Binding Site for the Endogenous Agonist, Small-Molecule Agonists, and Ago-allosteric Modulators on the Ghrelin Receptor

Ghrelin Receptor Modulators and Their Therapeutic Potential

Synthesis and Anti-Proliferative Activity of Biphenyl Derived 5-Substituted-Indolin-2-Ones

Contact Info

Product

Resources

About